Skip to search formSkip to main contentSkip to account menu

CRA 026440

Known as: CRA-026440, CRA026440 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Histone deacetylase inhibitorHydroxamic AcidsIndoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
INFRARED SPECTROSCOPY OF SYMBIOTIC STARS. VIII. ORBITS FOR THREE S-TYPE SYSTEMS: AE ARAE, Y CORONAE AUSTRALIS, AND SS 73-147
With new infrared radial velocities we have computed orbits of the M giants in three southern S-type symbiotic systems. AE Ara… 
2006
2006
CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo
CRA-026440 is a novel, broad-spectrum, hydroxamic acid–based inhibitor of histone deacetylase (HDAC) that shows antitumor and… 
2006
2006
The effects of histone deacetylase (HDAC) inhibitor, CRA-026440, on angiongenesis, signal transduction and tumor growth.
5047 Histone acetylation is one mechanism by which chromatin structure and its transcription is regulated. Histone acetylation… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)